Brief: Duality Biotherapeutics FY Revenue Rmb1.85 Billion
23/03/2026 15:31
March 23 (Reuters) - Duality Biotherapeutics Inc 9606.HK: FY REVENUE RMB1.85 BILLION LOSS FOR YEAR ATTRIBUTABLE RMB2.59 BILLION Further company coverage: 9606.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Duality Biotherapeutics
See all newsDuality Biotherapeutics rises most in near six weeks on Roche's Genentech tie-up
Brief: Duality Biotherapeutics Says Global Research And Development Collaboration And License Agreement With Genentech
Brief: Duality Biotherapeutics Obtains Acceptance From Shanghai Securities Regulatory Bureau For Counselling On Proposed RMB Share Listing
Brief: Duality Biotherapeutics Announces Share Repurchase Plan Of Up To $40 Million
Brief: Duality Biotherapeutics Approved Proposed RMB Share Issue On Sci-Tech Board